Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T87946
(Former ID: TTDI01559)
|
|||||
| Target Name |
Cytokine receptor unspecific (CRF)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 5 Target-related Diseases | + | ||||
| 1 | Acute myeloid leukaemia [ICD-11: 2A60] | |||||
| 2 | Head and neck cancer [ICD-11: 2D42] | |||||
| 3 | Rheumatoid arthritis [ICD-11: FA20] | |||||
| 4 | Squamous cell carcinoma [ICD-11: 2B60-2D01] | |||||
| 5 | Breast cancer [ICD-11: 2C60-2C6Y] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
| 1 | AD-452 | Drug Info | Phase 2 | Rheumatoid arthritis | [2] | |
| 2 | IRX-2 | Drug Info | Phase 2 | Head and neck cancer | [3] | |
| Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
| 1 | JTE-607 | Drug Info | Discontinued in Phase 2 | Sepsis | [4] | |
| 2 | VP-025 | Drug Info | Discontinued in Phase 1 | Alzheimer disease | [5] | |
| 3 | VG-106 | Drug Info | Terminated | Solid tumour/cancer | [6] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 4 Modulator drugs | + | ||||
| 1 | AD-452 | Drug Info | [1] | |||
| 2 | IRX-2 | Drug Info | [7] | |||
| 3 | VP-025 | Drug Info | [9] | |||
| 4 | VG-106 | Drug Info | [10] | |||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | JTE-607 | Drug Info | [8] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Detection of apoptosis by RT-PCR array in mefloquine-induced cochlear damage. Journal of Otology Volume 6, Issue 1, June 2011, Pages 1-9. | |||||
| REF 2 | ClinicalTrials.gov (NCT00141934) A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.. U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT00210470) A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer. U.S. National Institutes of Health. | |||||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014630) | |||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017461) | |||||
| REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025763) | |||||
| REF 7 | Clinical pipeline report, company report or official report of IRX Therapeutics. | |||||
| REF 8 | JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res. 1999 Aug;48(8):461-8. | |||||
| REF 9 | List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Dis 2007;4:443-486. | |||||
| REF 10 | WO patent application no. 2011,0955,45, Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.